Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Research & Development (2017 - 2026)

Denali Therapeutics has reported Research & Development over the past 9 years, most recently at $97.9 million for Q4 2025.

  • Quarterly Research & Development fell 1.89% to $97.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $418.8 million through Dec 2025, up 5.63% year-over-year, with the annual reading at $418.8 million for FY2025, 5.63% up from the prior year.
  • Research & Development was $97.9 million for Q4 2025 at Denali Therapeutics, down from $101.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $128.8 million in Q1 2023 and troughed at $60.2 million in Q1 2021.
  • The 5-year median for Research & Development is $95.1 million (2022), against an average of $93.2 million.
  • Year-over-year, Research & Development skyrocketed 49.62% in 2023 and then decreased 16.92% in 2024.
  • A 5-year view of Research & Development shows it stood at $67.9 million in 2021, then surged by 35.7% to $92.1 million in 2022, then grew by 17.04% to $107.8 million in 2023, then dropped by 7.44% to $99.8 million in 2024, then decreased by 1.89% to $97.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Research & Development are $97.9 million (Q4 2025), $101.9 million (Q3 2025), and $102.7 million (Q2 2025).